Piramal divests diagnostics arm to SRL, to retain 10% in new combine
This article was originally published in Scrip
Executive Summary
Piramal Healthcare has divested its pathology and radiology diagnostic services subsidiary to Super Religare Laboratories (SRL) for Rs6.0 billion ($128.3 million), its second major deal in less than two months following the sale of its domestic formulations business to Abbott.